ID   PC-9/ER1
AC   CVCL_D778
SY   PC-9-ER1; PC9-ER1
DR   cancercelllines; CVCL_D778
DR   Cosmic; 1731371
DR   Wikidata; Q54938489
RX   PubMed=22815900;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 19
RX   PubMed=22815900; DOI=10.1371/journal.pone.0041017;
RA   Tabara K., Kanda R., Sonoda K., Kubo T., Murakami Y., Kawahara A.,
RA   Azuma K., Abe H., Kage M., Yoshinaga A., Tahira T., Hayashi K.,
RA   Arao T., Nishio K., Rosell R., Kuwano M., Ono M.;
RT   "Loss of activating EGFR mutant gene contributes to acquired
RT   resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.";
RL   PLoS ONE 7:E41017-E41017(2012).